CMG Pharmaceutical Co., Ltd. (KOSDAQ:058820)
South Korea
· Delayed Price · Currency is KRW 1,970.00
+21.00 (1.08%)
Apr 1, 2025, 3:30 PM KST
CMG Pharmaceutical Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2019 | FY 2018 | 2017 - 2013 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '19 Dec 31, 2019 | Dec '18 Dec 31, 2018 | 2017 - 2013 |
| Operating Revenue | 99,100 | 93,907 | 82,197 | 58,623 | 49,865 | Upgrade
|
| Other Revenue | - | - | - | 0 | - | Upgrade
|
| Revenue | 99,100 | 93,907 | 82,197 | 58,623 | 49,865 | Upgrade
|
| Revenue Growth (YoY) | 5.53% | 14.24% | 40.21% | 17.56% | 20.05% | Upgrade
|
| Cost of Revenue | 53,456 | 50,315 | 41,446 | 29,738 | 27,175 | Upgrade
|
| Gross Profit | 45,643 | 43,592 | 40,752 | 28,885 | 22,690 | Upgrade
|
| Selling, General & Admin | 38,987 | 35,675 | 32,341 | 22,437 | 17,646 | Upgrade
|
| Research & Development | 1,454 | 2,181 | 3,312 | 1,993 | 777.8 | Upgrade
|
| Other Operating Expenses | 1,290 | 1,084 | 1,120 | 781.85 | 593.94 | Upgrade
|
| Operating Expenses | 44,623 | 40,555 | 37,770 | 26,281 | 20,120 | Upgrade
|
| Operating Income | 1,020 | 3,037 | 2,981 | 2,604 | 2,570 | Upgrade
|
| Interest Expense | -2,512 | -79.54 | -15.28 | -8.59 | - | Upgrade
|
| Interest & Investment Income | 3,130 | 3,752 | 1,963 | 1,100 | 502.12 | Upgrade
|
| Earnings From Equity Investments | 2,620 | 4,308 | - | - | - | Upgrade
|
| Currency Exchange Gain (Loss) | 5,634 | 210.08 | 2,054 | 279.83 | -8.44 | Upgrade
|
| Other Non Operating Income (Expenses) | 3,747 | -1,112 | 64.49 | -581.33 | 91.65 | Upgrade
|
| EBT Excluding Unusual Items | 13,640 | 10,116 | 7,048 | 3,393 | 3,155 | Upgrade
|
| Gain (Loss) on Sale of Investments | -9,616 | -3,138 | -7,951 | 534.01 | 612.06 | Upgrade
|
| Gain (Loss) on Sale of Assets | -11 | -4.09 | -22.76 | 0.5 | 2.58 | Upgrade
|
| Asset Writedown | -1,133 | -241.97 | -329 | -91.25 | -114.1 | Upgrade
|
| Pretax Income | 2,880 | 6,731 | -1,255 | 3,837 | 3,656 | Upgrade
|
| Income Tax Expense | 185.61 | 275.68 | -866.96 | 785.44 | -2,409 | Upgrade
|
| Earnings From Continuing Operations | 2,695 | 6,455 | -388.14 | 3,051 | 6,065 | Upgrade
|
| Net Income | 2,695 | 6,455 | -388.14 | 3,051 | 6,065 | Upgrade
|
| Net Income to Common | 2,695 | 6,455 | -388.14 | 3,051 | 6,065 | Upgrade
|
| Net Income Growth | -58.26% | - | - | -49.69% | 113.94% | Upgrade
|
| Shares Outstanding (Basic) | 142 | 140 | 139 | 122 | 109 | Upgrade
|
| Shares Outstanding (Diluted) | 539 | 140 | 139 | 122 | 109 | Upgrade
|
| Shares Change (YoY) | 284.04% | 1.04% | 14.27% | 11.63% | -0.14% | Upgrade
|
| EPS (Basic) | 19.00 | 46.00 | -2.79 | 25.10 | 55.70 | Upgrade
|
| EPS (Diluted) | 5.00 | 46.00 | -3.00 | 25.00 | 55.70 | Upgrade
|
| EPS Growth | -89.13% | - | - | -55.12% | 114.23% | Upgrade
|
| Free Cash Flow | -27,808 | -8,446 | -3,444 | -5,352 | -1,659 | Upgrade
|
| Free Cash Flow Per Share | -51.60 | -60.19 | -24.80 | -44.03 | -15.24 | Upgrade
|
| Gross Margin | 46.06% | 46.42% | 49.58% | 49.27% | 45.50% | Upgrade
|
| Operating Margin | 1.03% | 3.23% | 3.63% | 4.44% | 5.15% | Upgrade
|
| Profit Margin | 2.72% | 6.87% | -0.47% | 5.21% | 12.16% | Upgrade
|
| Free Cash Flow Margin | -28.06% | -8.99% | -4.19% | -9.13% | -3.33% | Upgrade
|
| EBITDA | 4,366 | 5,595 | 5,266 | 4,709 | 4,416 | Upgrade
|
| EBITDA Margin | 4.41% | 5.96% | 6.41% | 8.03% | 8.86% | Upgrade
|
| D&A For EBITDA | 3,346 | 2,558 | 2,284 | 2,106 | 1,846 | Upgrade
|
| EBIT | 1,020 | 3,037 | 2,981 | 2,604 | 2,570 | Upgrade
|
| EBIT Margin | 1.03% | 3.23% | 3.63% | 4.44% | 5.15% | Upgrade
|
| Effective Tax Rate | 6.44% | 4.10% | - | 20.47% | - | Upgrade
|
| Advertising Expenses | 1,557 | 1,644 | 1,682 | 616.29 | 830.83 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.